Shareholders saw the value of Altria Group stock tumble in late July 2026, shortly after the company reported second-quarter results. The investigation centers on statements made by CEO Billy Gifford during an April 30 earnings call. At that time, Gifford claimed the on! PLUS product was the only one authorized under an FDA pilot program and suggested that pending applications would likely receive regulatory approval within a 180-day window.
Altria Faces Shareholder Investigation Over Nicotine Pouch Claims
Conflict emerged this week as law firm Levi & Korsinsky launched an investigation into Altria Group, questioning the accuracy of management’s public statements regarding the FDA regulatory status of its on! PLUS nicotine pouches and the timeline for pending marketing authorizations.
Legal experts are now examining whether Altria failed to properly distinguish between the FDA’s pilot program and formal marketing authorization processes. Investigators suspect these characterizations may have misled investors about the true regulatory posture of the company’s nicotine portfolio. Those who purchased securities and incurred losses are currently being asked to provide trade confirmations and purchase records for a potential claims evaluation.
Comments (0)
No comments yet. Be the first!